Orbital Melanoma

Orbital melanoma is a cancer made from pigment-making cells called melanocytes that is found inside the eye socket (the orbit). The orbit is the bony space that holds the eyeball, the muscles that move the eye, the optic nerve, blood vessels, and fat. In orbital melanoma, cancer cells grow in this space and can push or pull on the eye and the tissues around it.

Orbital melanoma is a melanoma (a cancer that starts from pigment-making cells called melanocytes) that is present in the orbit—the bony socket that holds the eye and its supporting structures. It is very rare. It can be:

• Primary (starts in the orbit itself),

• Secondary (spreads into the orbit from nearby eye tissues such as the uvea inside the eye or the conjunctiva on the eye surface), or

• Metastatic (reaches the orbit from a melanoma elsewhere in the body, like the skin).

Orbital melanoma can appear in two main ways:

• It can be primary, meaning the melanoma starts in the orbit itself from melanocytes that live there (this is very rare).

• It can be secondary, meaning the melanoma comes to the orbit from somewhere else, such as the skin, the white of the eye surface (conjunctiva), the eyelid, or from inside the eye (uvea). In other words, it has spread or grown into the orbit.

Doctors agree that primary orbital melanoma is extremely rare (well under 1% of orbital tumors) and is often linked to pre-existing pigmented conditions like oculodermal melanocytosis or blue nevus. By contrast, secondary orbital melanoma is more common and may arrive years after a melanoma somewhere else was first found. MRI is very helpful, but a biopsy is usually needed to prove the diagnosis. In MRI scans, melanomas often look bright on T1 and dark on T2 because of the melanin pigment. BioMed CentralEyeWikiPMC+1

---

Types of orbital melanoma

1. Primary orbital melanoma (POM)
   This is melanoma that starts inside the orbit. It likely arises from melanocytes that live in the coverings of nerves or in tiny pigment nests inside the orbit. It is usually linked to long-standing pigmented lesions (like orbital melanocytosis or blue nevus). It is rare, but it needs careful treatment because it can grow and spread. EyeWikiPMC

2. Secondary orbital melanoma (metastatic or locally invasive)
   This means the melanoma reaches the orbit from another site. The most frequent sources are skin melanoma, conjunctival melanoma, eyelid melanoma, and uveal melanoma from inside the eye that grows through the eye wall (extrascleral extension) or recurs in the socket after eye removal (enucleation). It can also come from nearby areas like the sinuses. PMCEyeWiki

3. Orbital invasion by conjunctival melanoma
   A melanoma starting on the eye surface (conjunctiva) can creep backward into the orbit. Doctors may check the sentinel lymph node in the eyelid or parotid/preauricular area because conjunctival melanoma can spread to lymph nodes early. PMCAAO JournalJAMA Network

4. Orbital involvement from uveal melanoma
   A melanoma that starts inside the eye (uvea—choroid, ciliary body, or iris) can break through the eye wall (extrascleral extension) and grow into the orbit, or it can recur in the orbit after enucleation. Even though most uveal melanomas prefer to spread to the liver, orbital extension or recurrence can still happen and worsens the outlook. NatureCanadian Journal of OphthalmologyPMC

5. Metastasis to the extraocular muscles or orbital fat
   Skin melanoma cells may travel through the bloodstream and seed the muscles that move the eye or the fat in the socket, causing double vision and bulging. EyeWikiScienceDirect

---

Causes

These “causes” explain how orbital melanoma can appear in the orbit or what increases the chance that it will appear there. Some are direct sources of the tumor; others are risk factors that make melanoma more likely somewhere else (which can then reach the orbit).

1. Primary orbital melanoma from native orbital melanocytes
   Rarely, pigment cells inside the orbit turn cancerous and form melanoma right there. PMC

2. Orbital melanocytosis
   This is extra pigment in the tissues of the orbit. Long-standing pigment conditions like this can give rise to primary orbital melanoma later in life. EyeWiki

3. Oculodermal melanocytosis (Nevus of Ota)
   This condition causes slate-gray or blue patches around the eye and sometimes inside the eye. It is linked to melanoma risk and can be associated with primary orbital melanoma. EyeWiki

4. Blue nevus or cellular blue nevus in the orbit
   A deep, pigmented “mole” (nevus) in the orbit can, in rare cases, transform into melanoma. EyeWiki

5. Melanocytes along the optic nerve sheath
   Pigment cells in the coverings of the optic nerve can become malignant and form an orbital melanoma. ScienceDirect

6. Spread from skin (cutaneous) melanoma
   A melanoma that started on the skin—face, scalp, or even the trunk—can travel in the blood and land in the orbit, sometimes in the eye muscles. PMCEyeWiki

7. Spread from conjunctival melanoma
   A melanoma from the eye surface can grow backward into the orbit or spread to lymph nodes first and then to the orbit. PMC

8. Spread from eyelid melanoma
   A melanoma in the eyelid skin can invade deeper and extend into the orbit over time. (Risk is evaluated similarly to other skin melanomas.) AAO Journal

9. Extrascleral extension from uveal melanoma
   A melanoma inside the eye can break through the white coat (sclera) and grow into the orbit. Nature

10. Orbital recurrence after enucleation for uveal melanoma
    Rarely, microscopic melanoma cells left behind or seeded at surgery can grow later in the socket (implant-site or orbital recurrence). PMC

11. Direct spread from sinonasal mucosal melanoma
    A melanoma starting in the nose or sinuses can break into the orbit because the bony walls are thin. (This is a form of local extension.) PMC

12. Lacrimal sac or lacrimal system melanoma
    Melanoma in the tear drainage system is rare but can enter the orbit as it enlarges. (This is another pathway of direct extension.)

13. Metastasis to extraocular muscles
    Skin melanoma often seeds the eye muscles, causing double vision and eye bulging. (This is a signature pattern doctors watch for.) EyeWiki

14. Hematogenous spread (through the bloodstream)
    Melanoma cells commonly spread by blood. The orbit has rich blood supply, so tumor cells can lodge there. PMC

15. Lymphatic spread from ocular surface or eyelid
    Conjunctival and eyelid melanomas can reach lymph nodes, and from there, cancer can show up near the orbit. Sentinel lymph node biopsy helps detect early nodal spread. PMC

16. Family history and genetic susceptibility (especially for cutaneous melanoma)
    Having close relatives with melanoma, or mutations like CDKN2A in families, increases overall melanoma risk; a melanoma that occurs elsewhere can later involve the orbit. (General melanoma risk factor.) EyeWiki

17. Light skin, many moles, blue eyes, red or fair hair
    These features raise the chance of skin melanoma, which can later metastasize to the orbit. (Again, a risk for the primary melanoma.) EyeWiki

18. Excess ultraviolet (UV) exposure
    High lifetime sun or tanning bed exposure increases the chance of skin melanoma, which may later show up in the orbit. EyeWiki

19. Immunosuppression
    Weakened immunity (for example after organ transplant or in certain illnesses) raises melanoma risk and can allow spread. (General melanoma risk factor.) EyeWiki

20. Prior radiation or chronic scarring (rare links)
    Prior radiation or long-term tissue irritation can, rarely, be linked to melanoma formation in nearby skin or mucosa; if melanoma develops there, the orbit can be affected later.

---

Symptoms

1. Painless bulging of the eye (proptosis)
   The eye slowly looks more “pushed out.” The socket has a mass taking up space, and the eye moves forward.

2. Double vision (diplopia)
   The tumor can press on or grow within the eye muscles. The eyes no longer line up, so you see two images.

3. Blurred or reduced vision
   Pressure on the optic nerve or stretching of the eye can make sight weaker or less sharp over time.

4. Eye or orbital pain or pressure
   Some people feel a dull ache or heaviness in or around the eye, especially when the mass grows or nerves are involved.

5. A visible mass or swelling in the eyelid or corner of the eye
   You may notice a lump, fullness, or puffiness that was not there before.

6. Dark spot or patch (pigmentation) on the eye surface or eyelid
   A new, enlarging, or irregular dark area can be a warning sign—especially if it changes shape or color.

7. Redness or irritation
   The surface of the eye can get red if the mass rubs or causes inflammation.

8. Watery eye (tearing)
   The tear system may not drain properly because the tumor presses on it.

9. Droopy eyelid (ptosis)
   Weight or nerve involvement can make the upper lid hang lower than normal.

10. Restricted eye movement
    The eye feels “stiff.” Looking in certain directions may be hard or painful.

11. Loss of side vision or blind spots
    If the optic nerve or parts of the visual pathway are affected, pieces of the visual field can go missing.

12. Flashes or floaters (when intraocular melanoma coexists)
    If melanoma is also inside the eye, people may notice sparkles of light or small moving specks.

13. Headache or facial numbness
    If nerves in the orbit or cheek are pressed, there can be pain, tingling, or numbness.

14. Nose blockage or nosebleeds
    If the tumor grows from or into the sinuses, there may be stuffiness or bleeding.

15. Unintended weight loss or fatigue
    These whole-body signs can occur when cancer is advanced or has spread.

(Notes: Many people with primary orbital melanoma first notice painless proptosis and later develop vision or double-vision symptoms. When melanoma reaches the orbit from somewhere else, symptoms can start months to decades after the first melanoma was treated. MRI patterns—bright on T1, dark on T2—often suggest melanoma, but biopsy confirms it.) PMC+1

---

Diagnostic tests

A) Physical examination

1. Medical history and full-body skin check
   The doctor asks about past or current melanomas anywhere on the body, family history, sun exposure, and time course of symptoms. The skin, eyelids, conjunctiva, and nearby lymph nodes are examined for any suspicious pigmented spots or lumps. This is vital because orbital melanoma often comes from another site. PMC

2. External eye inspection and palpation
   The doctor looks for bulging, displacement of the eye, swelling, color changes, and visible masses, and gently feels the tissues around the orbit to check firmness and tenderness.

3. Visual acuity and color vision
   Simple charts measure clarity of sight, and color tests check for early optic nerve dysfunction (colors may look washed out if the nerve is compressed).

4. Pupil tests (looking for a relative afferent pupillary defect)
   Unequal pupil reactions can signal optic nerve pressure or damage caused by the mass.

5. Eye movement and alignment tests
   The doctor watches how the eyes track in all directions and checks for misalignment that could cause double vision.

B) Manual tests

6. Hertel exophthalmometry
   This is a simple measurement with a special ruler that tells how far each eye protrudes. A larger number on one side supports true proptosis.

7. Resistance to retropulsion
   The doctor gently presses the eye backward through the eyelid. A firm, “non-springy” feel may mean there is a solid mass in the orbit.

8. Forced-duction test
   Under numbing drops (and often in the operating room if needed), the eye is gently grasped at the surface to see if a muscle is physically restricted by a mass.

C) Laboratory & pathology

9. Biopsy of the orbital mass
   A small tissue sample is taken surgically (incisional or excisional) and examined under the microscope. Biopsy is the gold standard to confirm melanoma in the orbit. In specific settings of diffuse ocular melanocytosis, clinicians may avoid unnecessary biopsies to reduce any risk of spread, and they choose surgery carefully. EyeWiki

10. Immunohistochemistry
    Stains such as S100, HMB-45, Melan-A, and SOX10 help prove the cells are melanoma cells (melanocytic markers).

11. Molecular and cytogenetic profiling
    Where relevant, doctors may test for mutations (for example BRAF, NRAS, KIT in many cutaneous/mucosal melanomas; GNAQ/GNA11 and chromosome changes like monosomy 3 in uveal melanoma) to guide prognosis or systemic therapy.

12. Baseline blood tests
    Blood work such as CBC, liver function tests, and LDH helps with staging and overall assessment because melanoma can spread to the liver and other organs. (LDH is sometimes used as a tumor burden marker.)

D) Electrodiagnostic tests

13. Visual evoked potentials (VEP)
    This test records tiny brain waves in response to light patterns. It helps detect optic nerve problems caused by pressure from an orbital tumor.

14. Electroretinography (ERG)
    This measures electrical activity of the retina. It is most helpful if there is a question about retinal function when an intraocular tumor might also be present.

E) Imaging tests

15. MRI of the orbits with contrast
    This is usually the best scan for soft tissue detail. Melanin often makes melanoma look bright on T1-weighted images and dark on T2-weighted images, which is a useful clue. MRI also shows whether the mass touches the optic nerve, muscles, or brain. PMCRadiopaedia

16. CT scan of the orbits
    CT is good for bone changes. It can show if the tumor is eroding the thin bones around the orbit or extending from nearby sinuses.

17. Ocular ultrasound (B-scan) or ultrasound biomicroscopy
    If there is concern the tumor started inside the eye (uveal melanoma), ultrasound helps measure tumor height and see extrascleral extension through the eye wall. Radiopaedia

18. Whole-body PET-CT (or PET-MRI) for staging
    This looks for active cancer in the rest of the body and helps plan treatment for melanoma that may have spread.

19. CT chest/abdomen/pelvis and targeted liver imaging
    Because melanoma—especially uveal melanoma—often heads to the liver, doctors image the liver carefully when staging. EyeWiki

20. Brain MRI
    If there are neurological symptoms or advanced disease, a brain MRI is done. Like orbital tumors, melanoma in the brain often looks bright on T1 and dark on T2, partly due to melanin or blood products. RadiopaediaPMC

Non-Pharmacological Treatments (therapies & “other” supports)

These are treatments and supports that don’t involve systemic medications. Some are local anti-cancer therapies (like radiation), others are rehabilitative or supportive. Your team will tailor a plan.

1. External-Beam Radiation Therapy (EBRT, e.g., IMRT):
   What it is: Focused X-rays from outside the body.
   Purpose: Control residual orbital disease after surgery, or treat inoperable lesions.
   How it works: Damages tumor DNA to stop growth. Modern IMRT shapes dose to spare normal tissues.

2. Stereotactic Radiosurgery (CyberKnife/Gamma Knife to the orbit):
   What: Very precise, high-dose radiation in 1–5 sessions.
   Purpose: Local control of small, well-defined orbital lesions.
   How: Pinpoint beams converge on the tumor, limiting dose to nearby structures.

3. Proton Beam Therapy (for eye/adjacent disease):
   What: Charged particles deposit energy at a set depth.
   Purpose: Globe-sparing treatment for selected intraocular tumors close to the orbit.
   How: “Bragg peak” allows sharp dose fall-off past the target.

4. Plaque Brachytherapy (for uveal melanoma that threatens the orbit):
   What: A tiny radioactive “plaque” is sewn to the eye wall for a few days.
   Purpose: Local tumor control while keeping the eye.
   How: Delivers radiation directly to the tumor with steep dose fall-off.

5. Cryotherapy (for conjunctival margins):
   What: Controlled freezing of tissue edges after surgical excision.
   Purpose: Kills microscopic cells around the cut edges to reduce recurrence.
   How: Ice crystals disrupt cell membranes; used by ocular oncologists.

6. Transpupillary Thermotherapy/Photocoagulation (selected intraocular cases):
   Purpose: Supplemental heat/laser therapy to damage small residual tumor foci.
   How: Raises local temperature to cause tumor cell death.

7. Site-tailored Orbitotomy and Debulking (when complete removal isn’t possible):
   Purpose: Relieve pressure, improve comfort, reduce tumor burden before radiation.
   How: Targeted surgical approach to the lesion’s location.

8. Orbital Exenteration (reserved cases):
   Purpose: Remove all orbital contents when disease cannot be controlled otherwise.
   How: Radical surgery; followed by rehabilitation with an orbital prosthesis.

9. Sentinel Lymph Node Biopsy and Nodal Surveillance (conjunctival melanoma):
   Purpose: Early pick-up of microscopic spread to regional nodes in at-risk conjunctival tumors.
   How: Dye/radio-tracer maps the “first” node for biopsy; guides further therapy.

10. Low-Vision Rehabilitation:
    Purpose: Maximize remaining vision with training/tools (magnifiers, contrast tips, lighting).
    How: Occupational therapy techniques retrain daily tasks to maintain independence.

11. Ocular/Orbital Prosthetic Fitting (after exenteration or enucleation):
    Purpose: Restore appearance, improve confidence, support eyelid function.
    How: An ocularist designs a custom prosthesis.

12. Prism or Strabismus Management for Double Vision:
    Purpose: Align images to reduce diplopia after surgery or radiation.
    How: Prism glasses or, later, corrective muscle surgery.

13. Pain and Symptom Self-Management Skills (non-drug):
    Purpose: Ease headaches, eye pressure, and anxiety.
    How: Cold/warm compresses, relaxation breathing, mindfulness, and pacing under clinician guidance.

14. Nutritional Counseling during Cancer Care:
    Purpose: Maintain weight and strength; manage treatment-related eating issues.
    How: Dietitians tailor a plant-forward, high-protein plan; follow ACS/ASCO guidance.

15. Psychological Counseling and Peer Support:
    Purpose: Manage fear, body-image changes, and stress; improve quality of life.
    How: Cognitive-behavioral therapy, support groups, and survivorship programs.

16. Physical Activity Program (as able):
    Purpose: Fight fatigue, maintain muscle, lift mood during therapy.
    How: ASCO recommends regular, safe exercise during cancer treatment.

17. Smoking Cessation Support:
    Purpose: Improve healing, reduce second cancers, protect heart/lung health.
    How: Behavioral programs; if medications are needed, your team will advise.

18. UV and Eye Protection:
    Purpose: Reduce additional UV injury to ocular surfaces and lids.
    How: UV-blocking wraparound sunglasses and wide-brim hats. (This does not treat melanoma but is sensible prevention.)

19. Clinical-Trial Enrollment (when eligible):
    Purpose: Access promising therapies (e.g., new immune or targeted agents) that are not yet standard.
    How: Your oncologist matches your tumor profile with open studies.

20. Palliative Radiotherapy or Procedures (for symptoms from advanced disease):
    Purpose: Reduce pain, pressure, or bleeding; improve comfort and function.
    How: Tailored short-course radiation or minor procedures.

---

Drug Treatments

Important: Doses below are typical label doses for melanoma in adults (not individualized). Your oncologist adjusts dosing, schedules, and combinations. Some therapies work much better in conjunctival/skin-like melanoma than in uveal melanoma (inside the eye). Uveal melanoma often needs uveal-specific strategies like tebentafusp when eligible.

1. Tebentafusp-tebn (IMCgp100) – TCR bispecific (for HLA-A*02:01)
   Dose: Step-up weekly: 20 µg day 1 → 30 µg day 8 → 68 µg day 15, then 68 µg weekly IV.
   When: Metastatic or unresectable uveal melanoma in HLA-A*02:01–positive adults.
   Purpose: Prolong survival in metastatic uveal melanoma.
   How: One end binds gp100 peptide on melanoma cells (via a T-cell receptor), the other end recruits T cells (anti-CD3) to kill the cancer cell.
   Key side effects: Cytokine-release symptoms (fever, chills, low blood pressure), rash, liver tests up.

2. Pembrolizumab (Keytruda) – PD-1 inhibitor (immunotherapy)
   Dose: 200 mg IV q3 weeks or 400 mg q6 weeks.
   When: Unresectable/metastatic melanoma; more effective in conjunctival/skin-type melanoma than in uveal melanoma.
   Purpose: Unleash T-cells to attack melanoma.
   How: Blocks PD-1 checkpoint on T-cells.
   Key side effects: Immune-related inflammation (skin, thyroid, colon, lung, liver).

3. Nivolumab (Opdivo) – PD-1 inhibitor
   Dose: 240 mg IV q2 weeks or 480 mg q4 weeks (monotherapy).
   When/Purpose/How/Side effects: Similar to pembrolizumab; also used with ipilimumab in certain settings.

4. Ipilimumab (Yervoy) – CTLA-4 inhibitor
   Dose (mono): 3 mg/kg IV q3 weeks × 4 doses.
   When: Sometimes combined with PD-1 therapy for higher response at the cost of higher toxicity.
   How: Releases an early “brake” on T-cell activation.
   Key side effects: Higher rates of immune colitis, hepatitis, endocrine issues.

5. Nivolumab + Ipilimumab (combination immunotherapy)
   Common regimen: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg IV q3 weeks × 4, then nivolumab maintenance (240 mg q2 weeks or 480 mg q4 weeks).
   When: Unresectable/metastatic melanoma where higher response is worth higher toxicity; uveal responses are limited overall.
   Key side effects: Immune toxicities are more frequent/severe than with single-agent therapy.

6. Relatlimab + Nivolumab (Opdualag) – LAG-3 + PD-1 inhibition
   Dose: Relatlimab 160 mg + nivolumab 480 mg IV q4 weeks (fixed dose).
   When: First-line option for unresectable/metastatic melanoma (mostly studied in cutaneous melanoma).
   Purpose/How: Dual checkpoint blockade may improve responses while balancing toxicity.
   Side effects: Immune-related events; generally less severe than ipi+nivo.

7. Dabrafenib + Trametinib – BRAF inhibitor + MEK inhibitor
   Dose: Dabrafenib 150 mg PO twice daily + trametinib 2 mg PO daily.
   When: Only for tumors proven BRAF-V600–mutant (seen in some conjunctival melanomas; not typical of uveal melanoma).
   Purpose: Block the MAPK pathway driving growth.
   Side effects: Fever, fatigue, rash, hand-foot syndrome, high blood pressure, heart/eye monitoring for MEK drugs.

8. Encorafenib + Binimetinib – BRAF + MEK inhibition
   Dose: Encorafenib 450 mg PO daily + binimetinib 45 mg PO twice daily.
   When/Purpose/How/Side effects: As above for BRAF-mutant disease.

9. Vemurafenib (± Cobimetinib) – BRAF (± MEK) inhibition
   Dose (vemurafenib): 960 mg PO twice daily; cobimetinib if added per label.
   When: BRAF-mutant conjunctival/skin-type melanoma.
   Side effects: Rash, photosensitivity (strict sun protection), QT prolongation; MEK-related eye/heart monitoring if combined.

10. Imatinib (or other KIT inhibitors) – KIT-targeted therapy
    Dose (imatinib): Often 400 mg PO daily (dosing varies).
    When: KIT-mutant conjunctival melanoma (rare but actionable).
    Purpose/How: Blocks KIT signaling that drives the tumor.
    Side effects: Fluid retention, fatigue, low blood counts.

Why not MEK inhibitors alone for uveal melanoma? Single-agent MEK inhibition (e.g., selumetinib) showed limited benefit in phase III studies; it is not standard care today for uveal melanoma. Clinical trials are ongoing with newer combinations (e.g., darovasertib, a PKC inhibitor, in trials), but these remain investigational.

---

Regenerative / Cell-Based” Therapies

These are advanced treatments used by oncology specialists. None are DIY “immune boosters.” Some are newly approved; others remain investigational or useful only in selected melanoma types. Always discuss eligibility and risks.

1. Lifileucel (AMTAGVI) – Tumor-Infiltrating Lymphocyte (TIL) therapy
   What: FDA-approved autologous T-cell therapy for advanced melanoma after prior treatments.
   How: Your tumor’s own T-cells are expanded in a lab, then reinfused after lymphodepleting chemo, followed by IL-2 support.
   Why: Offers responses in heavily pre-treated melanoma (data primarily in cutaneous).
   Note: Availability is specialized; uveal responses are still being defined.

2. Tebentafusp (listed above) – Immune-mobilizing TCR therapy for HLA-A*02:01 uveal melanoma; a major step forward for this subtype.

3. High-Dose Interleukin-2 (aldesleukin):
   What: Powerful T-cell activator used in selected, fit patients.
   How: Stimulates broad immune activation; can yield durable responses in a minority.
   Caution: Significant toxicity; use at experienced centers.

4. Oncolytic Virus Therapy (T-VEC):
   What: An injected, modified herpes virus that kills tumor cells and alerts the immune system.
   Where it fits: Mainly for injectable cutaneous melanoma lesions; not typical for orbital/uveal disease but may be considered for selected accessible deposits.

5. Relatlimab + Nivolumab (dual checkpoint) – included above; reinforces T-cell function via two checkpoints.

6. Clinical-Trial Cell or Gene Therapies:
   What: Investigational options such as new engineered T-cell receptors for uveal melanoma or PKC pathway inhibitors combined with other agents.
   Why: Uveal melanoma biology differs from skin melanoma; trials seek better systemic control. (Ask your team about trial matching.)

---

Surgeries

1. Orbitotomy with Tumor Excision (when feasible):
   What: Targeted surgery to remove a well-defined orbital melanoma.
   Why: Achieve local control with eye preservation when margins are possible.

2. Debulking/Partial Resection:
   What: Remove as much tumor as safely possible when it’s too diffuse for full excision.
   Why: Reduce pressure symptoms and prepare for adjuvant radiation.

3. Orbital Exenteration (last-resort, eye-sacrificing surgery):
   What: Remove all orbital contents; sometimes extended to nearby bone if invaded.
   Why: Life-saving local control when disease is not otherwise controllable; prosthetic rehabilitation follows.

4. Enucleation (remove the eye) for large intraocular melanoma threatening the orbit):
   What: Eye removal with a segment of optic nerve.
   Why: For very large, painful, or visionless eyes with tumor not suitable for globe-sparing therapy.

5. Sentinel Lymph Node Biopsy / Lymphadenectomy (conjunctival melanoma):
   What: Identify and remove the “first-draining” node; remove involved nodal basin if positive.
   Why: Early staging and control of nodal disease for selected tumor sizes/thicknesses.

---

Prevention Tips

These steps reduce additional risk and support wellbeing. They do not replace medical treatment.

1. UV protection for eyes/eyelids: UV-blocking wraparound sunglasses + hat.

2. Avoid tanning beds.

3. Regular eye checks—especially if you have oculodermal melanocytosis or a BAP1-related family history.

4. Know your baseline: seek evaluation for any new eye bulging, double vision, or pigmented eye spot that changes.

5. Healthy weight, daily activity, plant-forward diet (overall cancer prevention guidance).

6. Do not smoke; if you do, get help to quit.

7. Sun-smart skin habits for whole-body melanoma prevention (shade, clothing, SPF).

8. Family awareness: relatives of BAP1 families should ask about genetics and eye surveillance.

9. Medication interaction awareness (e.g., with targeted drugs): confirm grapefruit/herb interactions with your oncology pharmacist.

10. Vaccinations as advised (e.g., flu), timed around therapy per your oncology team.

---

When should I see a doctor urgently?

• New or worsening symptoms: sudden eye bulging, double vision, new dark spot on eye surface, eyelid mass, eye pain, or vision drop.

• Systemic signs: unexplained weight loss, new persistent cough, bone pain, or liver discomfort if you’ve had uveal melanoma (because of its liver tendency).

• After treatment: any fever, rash, severe diarrhea, shortness of breath, or yellowing eyes/skin during immunotherapy—these may be immune side effects that need prompt evaluation.

---

What to Eat” and “What to Avoid

What to eat (most days):

1. Plenty of vegetables and fruits (aim for ≥ 2.5–3 cups veg + 1.5–2 cups fruit daily).

2. Whole grains (brown rice, oats, whole-wheat roti).

3. Lean proteins (fish, eggs, poultry, beans, lentils, tofu).

4. Healthy fats (nuts, seeds, olive/mustard oil).

5. Adequate protein at each meal to maintain weight and strength during treatment.

What to limit/avoid:

1. Highly processed meats and sugary drinks—linked with worse overall cancer risk.
2. Excess alcohol (or avoid entirely, per your team).
3. Raw or unpasteurized foods if your counts are low or you’re on treatments that raise infection risk—follow food-safety rules.
4. High-dose antioxidant or herbal supplements without your oncologist’s approval—they can interact with treatment.
5. Probiotic pills during immunotherapy without team approval; current data suggest dietary fiber and naturally fermented foods may be better than pills for supporting the microbiome.

---

Dietary “Molecular” Supplements

Evidence in melanoma is mixed. Use only if your team agrees, watch for interactions, and base doses on accepted nutrition guidance—not megadoses.

1. Vitamin D3 (if deficient):
   Typical dose: 800–2000 IU/day (adjust to blood level; avoid > 4000 IU/day unless prescribed).
   Function: Bone/immune support; low D is common and has been linked to worse melanoma outcomes in some studies.
   Mechanism: Steroid-hormone effects on immunity and cell growth.

2. Omega-3 fatty acids (EPA/DHA):
   Dose: ~1 g/day combined EPA/DHA (food first; capsules if approved).
   Function: Anti-inflammatory support; may help appetite and triglycerides.
   Mechanism: Competes with arachidonic acid pathways.

3. Protein supplements (whey/pea) when intake is poor:
   Dose: 20–30 g between meals as advised.
   Function: Preserve lean mass during therapy.
   Mechanism: Provides essential amino acids.

4. Vitamin B12/folate (only if deficient):
   Dose: As per lab-guided replacement.
   Function: Supports blood cell production, reduces neuropathy risk if low.
   Mechanism: DNA synthesis pathways.

5. Iron (if iron-deficiency is confirmed):
   Dose: Per labs (elemental iron 40–65 mg daily or on alternate days).
   Function: Correct anemia; improves energy.
   Mechanism: Hemoglobin production.

6. Calcium (if intake is low and vitamin D is supplemented):
   Dose: Typically to reach total 1000–1200 mg/day from food + supplement.
   Function: Bone health.
   Mechanism: Mineral for bone remodeling.

7. Zinc (short courses for taste changes, if low):
   Dose: Commonly 25–50 mg/day short-term with medical advice.
   Function: May help taste recovery; supports immune enzymes.
   Mechanism: Cofactor for many proteins.

8. Probiotic foods (not pills unless approved):
   Dose: Daily fermented foods (yogurt, kefir, kimchi) as tolerated.
   Function: Microbiome diversity; observational links to better immunotherapy outcomes with high-fiber diets.
   Mechanism: Gut–immune crosstalk.

9. Fiber (psyllium or food-based):
   Dose: Gradually to 25–30 g/day total fiber.
   Function: Supports gut health; observational link to better ICI responses (dietary fiber).
   Mechanism: SCFA production and immune modulation.

10. Multivitamin (basic, once daily):
    Function: Back-up for days appetite is poor.
    Caution: Avoid “mega” antioxidant blends during radiation/ICIs unless your oncologist agrees.

---

Frequently Asked Questions

1) Is orbital melanoma the same as eye melanoma?
Not exactly. Orbital melanoma is in the orbit. Eye (uveal) melanoma starts inside the eye and can extend into the orbit. Conjunctival melanoma starts on the eye’s surface and can also spread behind the eye.

2) How rare is a primary orbital melanoma?
Very rare. Most “orbital melanomas” are secondary (from uveal or conjunctival sources) or metastatic from the skin.

3) What symptoms should raise concern?
Eye bulging, double vision, pain/pressure, a growing mass, or visual loss. Seek prompt evaluation.

4) Which scans are best?
MRI with contrast is usually best for soft tissues; melanomas often look bright on T1/dark on T2 because of melanin. CT shows bone. PET-CT looks for spread.

5) Do genetics matter?
Yes. Uveal melanoma is commonly driven by GNAQ/GNA11 pathway and BAP1/SF3B1/EIF1AX status affects risk. Conjunctival melanoma often carries BRAF/NRAS/KIT mutations. These differences matter for drug choices.

6) What treatments can spare the eye?
Depending on size/site: plaque brachytherapy, proton/EBRT, local resections, and systemic therapy. Large, invasive, or recurrent cases may still need enucleation or exenteration.

7) Is uveal melanoma treated with the same drugs as skin melanoma?
Often no. Classic PD-1/CTLA-4 immunotherapy has lower response in uveal melanoma. A newer, uveal-specific immunotherapy, tebentafusp, improves survival in HLA-A*02:01 patients.

8) What is lifileucel (TIL therapy)?
A personalized cell therapy approved for advanced melanoma after prior treatments. Your tumor-fighting T-cells are harvested, expanded, and reinfused.

9) If my tumor has a BRAF mutation, what then?
Targeted combinations like dabrafenib+trametinib or encorafenib+binimetinib are options (mainly for conjunctival/skin-type melanoma, not typical for uveal).

10) When is exenteration necessary?
When the disease is uncontrollable or threatens life/health despite other treatments. It’s a last resort with prosthetic rehab afterward.

11) Will diet cure melanoma?
No. A plant-forward, balanced diet helps you stay strong in treatment, but it does not replace medical therapy. Follow ACS/ASCO nutrition guidance and your dietitian’s plan.

12) Should I take supplements?
Only what your team approves. Treat deficiencies (e.g., vitamin D) and avoid “mega-dose” antioxidants or unproven herbs that can interact with therapy.

13) What follow-up do I need?
Regular imaging and eye exams; uveal melanoma survivors often get liver imaging because the liver is the most common site of spread. Your schedule is individualized.

14) Is sentinel lymph node biopsy needed for everyone?
No. It’s considered mainly for conjunctival melanoma that meets size/thickness/ulceration criteria to stage nodal risk.

15) How do I find clinical trials?
Ask your oncologist about national registries and trials suited to your tumor’s genetics and prior treatments (e.g., newer immune/targeted combinations).

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 19, 2025.

PDF Document For This Disease Conditions References